Auvelity FDA Approval Status for Alzheimer's Disease Agitation
Auvelity (dextromethorphan/bupropion) is NOT currently FDA-approved for agitation associated with Alzheimer's disease dementia. The drug is approved exclusively for major depressive disorder (MDD) in adults 1.
Current FDA-Approved Indication
The FDA label explicitly states that Auvelity is approved only for treating MDD in adults, with clinical trials demonstrating efficacy specifically in this population 1. The label clearly warns: "Auvelity is not approved for uses other than the treatment of MDD" 1.
Development Status for Alzheimer's Agitation
While Auvelity (dextromethorphan/bupropion combination) is being developed for Alzheimer's disease agitation, it has not received FDA approval for this indication 2. The drug is currently in clinical development for this use, with research literature identifying it as a "promising" compound in phase 3 trials for agitation in Alzheimer's disease 3, 4.
Key Distinction
- Approved: Major depressive disorder only
- Under investigation: Alzheimer's disease agitation (not yet approved)
Current Standard of Care for Alzheimer's Agitation
For agitation in Alzheimer's disease, the established treatment framework follows APA guidelines from 2016 5:
Treatment Algorithm:
First-line approach: Nonpharmacological interventions must be attempted and documented before considering antipsychotics 5
Pharmacological intervention criteria: Antipsychotics should only be used when agitation is severe, dangerous, and/or causes significant patient distress 5
Risk-benefit discussion: Before initiating antipsychotics, clinicians must discuss potential risks and benefits with the patient (if feasible) and surrogate decision makers 5
Dosing strategy: Start at low doses and titrate to minimum effective dose 5
Response assessment: If no clinically significant response after 4 weeks at adequate dose, taper and discontinue 5
Currently Approved Option
Brexpiprazole is the only FDA-approved medication specifically for agitation in Alzheimer's disease 3, 4, though its limited clinical efficacy has generated criticism 3.
Important Clinical Caveat
The confusion may stem from the fact that dextromethorphan/bupropion is actively being studied and discussed in the literature for Alzheimer's agitation 3, 4, 6, but regulatory approval and clinical development are distinct processes. Until FDA approval is granted for the Alzheimer's agitation indication, prescribing Auvelity for this purpose would constitute off-label use.